article thumbnail

Is that really ADHD? Why flawed trials may be misleading millions

Science Daily: Pharmacology News

Researchers reviewing nearly 300 top-tier ADHD drug trials found that half skipped the rigorous, expert-led evaluations needed to rule out other conditions like depression or schizophrenia.

article thumbnail

Tofersen

New Drug Approvals

“Biogen’s antisense ALS drug shows promise in early clinical trial” FierceBiotech. “Biogen’s ALS Drug Gets Partial Backing From FDA Panel” Bloomberg News. Tofersen , sold under the brand name Qalsody , is a medication used for the treatment of amyotrophic lateral sclerosis (ALS). [3]

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Vamorolone

New Drug Approvals

Hoffman, Efficacy and safety of vamorolone vs placebo and prednisone among boys with duchenne muscular dystrophy: a randomized clinical trial, JAMA Neurol. 19] The US Food and Drug Administration (FDA) approved vamorolone based on evidence from a single clinical trial of 121 boys with DMD who were 4 to <7 years of age.

FDA
article thumbnail

Inavolisib

New Drug Approvals

19] Society and culture Legal status In October 2024, the US Food and Drug Administration (FDA) approved inavolisib for the treatment of PIK3CA -mutant breast cancer based on the results from the INAVO120 trial. [3] 3] [6] [20] [21] The drug application was granted priority review and breakthrough therapy designations by the FDA. [3]

FDA
article thumbnail

Elacestrant 

New Drug Approvals

1] History The efficacy of elacestrant was evaluated in the EMERALD trial, which was a randomized, open-label, active-controlled, multicenter study involving 478 postmenopausal women and men with ER-positive, HER2-negative advanced or metastatic breast cancer. . 1] [4] It is taken by mouth. [1] 3] [7] PATENTS Cruskie MP, et al. PMC 9340905.

FDA
article thumbnail

Pirtobrutinib

New Drug Approvals

5] History Pirtobrutinib is manufactured by Eli Lilly and Company and was approved by the US Food and Drug Administration in January 2023, for the treatment of mantle cell lymphoma that has become refractory to other BTK inhibitors. [13] 6] The same trial was used to assess safety and efficacy. [6] Food and Drug Administration (FDA).

article thumbnail

Zilucoplan

New Drug Approvals

“International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 80” WHO Drug Information. 6] [9] [10] It is a complement inhibitor that is injected subcutaneously (under the skin). [6] 1] Zilucoplan is a 15 amino-acid, synthetic macrocyclic peptide with formula C172H278N24O55. . hdl : 10665/330907.

FDA